Picamilon

The core historical claim. In conscious cats, picamilon (sodium N-nicotinoyl-GABA) produced a significant increase in cerebral blood flow, inhibited neurogenic vasospasm, and reversed serotonin-induced hemodynamic disturbance ^{3Reference 3Mirzoian et al. · 1989AnimalThe new cerebrovascular preparation pikamilon — in vivo (conscious cats)View study →}.

Independent work showed dose-dependent dilation of pial arterioles (greatest in 10–20 µm vessels) and raised cortical microcirculation in rats and rabbits after IV, IP and systemic dosing ^{4Reference 4Author(s) · 1989Effect of pikamilon on cortical blood supply and pial arteriolar microcirculation — animalView study →}, and steady vasodilation under rest and gravitational stress ^{5Reference 5Author(s) · 1993Effect of pikamilon and fenibut on cerebral blood supply at rest and under gravitational exposure — animalView study →}.

Mechanistic studies suggest the cerebrovascular effect depends on GABA-receptor chloride channels — reduced by picrotoxin, but not blocked by bicuculline ^{6Reference 6Silkina et al. · 2005GABAergic mechanism of the cerebrovascular and neuroprotective effects of afobazole and picamilon — animalView study →} — consistent with the idea that released GABA, not intact picamilon, does the work ^{2Reference 2Santillo et al. · 2023In vitroPicamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets — in vitroView study →}.

All of this is animal data; no adequately controlled human perfusion trial was found.

Gap: Robust in animals but essentially unconfirmed in rigorous human studies, and the parent molecule itself binds no relevant target in vitro ^{2Reference 2Santillo et al. · 2023In vitroPicamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets — in vitroView study →}. There is no modern, blinded human cerebral-perfusion imaging trial at supplemental oral doses.

The only recent human signal. A 2024 open randomized comparative trial in 44 patients with stage I chronic cerebral ischemia (CCI) reported progressive MoCA gains (≈24.9 → 26.5 → 28.3 points) over 2 months plus improved sleep and autonomic function, concluding that ~2 months is the optimal course ^{7Reference 7Danilov et al. · 2024RCTIntegrative assessment of the effectiveness and safety of outpatient Picamilon — randomized controlled trialView study →}.

A 2024 open cohort of 50 stage II CCI patients (200 mg IV for 10 days, then 50 mg ×3/day for 60 days) reported significant MoCA improvement and endothelial-marker changes ^{8Reference 8Danilov et al. · 2024ObservationalClinical efficacy and safety of Picamilon in progressive chronic cerebral ischemia — open cohort studyView study →}.

A 2022 open multicenter RCT (n=278) found a Picamilon + Ginkgo combination beat ginkgo monotherapy on MMSE/MoCA over 90 days ^{9Reference 9Author(s) · 2022RCTChronic cerebral ischemia: Picamilon Ginkgo combination — multicenter randomized comparative studyView study →} — but that isolates the combination, not picamilon. A 2023 Russian review likewise argues for combination therapy in asthenia with cognitive dysfunction rather than picamilon alone ^{26Reference 26Author(s) · 2023ReviewAsthenia, mental fatigue and cognitive dysfunction — reviewView study →}.

Every trial here is open-label, unblinded, single-country and recent, against a backdrop of a molecule whose mechanism is in doubt.

Gap: No blinded, placebo-controlled, independently replicated trial; the strongest study tests a ginkgo combo, not picamilon alone, and the endpoints are rating scales rather than hard outcomes.

Picamilon’s cerebrovascular reputation was extended to the eye in small Russian series. In primary open-angle glaucoma with normalized intraocular pressure but declining vision, picamilon improved central and peripheral visual fields and light sensitivity without lowering IOP or blood pressure ^{10Reference 10Kolomoĭtseva et al. · 1994Clinical trialResults of pikamilon use in open-angle glaucoma — controlled clinical trialView study →}.

In pigmented retinal abiotrophy (80 patients), a 10-day IM course improved visual function and ocular hemodynamics, more so in early-stage disease ^{11Reference 11Author(s) · 1995Clinical trialUse of vasoactive pikamilon in pigmented retinal abiotrophy — clinical trialView study →}.

A further series of 48 patients with central chorioretinal dystrophies reported subjective and objective improvement in most eyes ^{28Reference 28Basinskiĭ et al. · 2001Pathogenetic treatment of central chorioretinal dystrophies with pikamilonView study →}.

These are old, open-label, hemodynamic-endpoint studies.

Gap: Small, unblinded, decades-old single-country data with surrogate (perfusion/visual-field) endpoints; no independent replication. A niche use, not a mainstream indication.

GABA-containing vitamin derivatives including picamilon increased mouse survival under hypoxia, unlike GABA itself ^{12Reference 12Author(s) · 1989Antihypoxic properties of GABA-containing vitamin derivatives — animalView study →}, and reviews of GABA-mimetics place picamilon among agents proposed to limit ischemic injury by combining GABAergic tone with improved perfusion ^{27Reference 27Mirzoian et al. · 2003ReviewNeuroprotective and cerebrovascular effects of GABA mimetics — reviewView study →}.

But head-to-head the record is unflattering: in a rat model of post-ischemic cerebral blood flow, emoxipin outperformed picamilon at preventing no-reflow ^{13Reference 13Author(s) · 1999Action of emoxipin, lithium oxybutyrate and pikamilon on ischemic brain circulation — animalView study →}, and in acute traumatic brain injury the comparator nooglutil (50 mg/kg) was more effective than picamilon even at 500 mg/kg at preserving mitochondrial respiration ^{14Reference 14Author(s) · 1997Effect of nootropic agents on brain mitochondrial oxidative phosphorylation in acute craniocerebral trauma — animalView study →}.

Picamilon also limited pinocytotic (but not tracer) blood–brain-barrier leakage in chronically alcohol-intoxicated rats ^{25Reference 25Author(s) · 1990AnimalEffects of drugs on blood–brain-barrier permeability in rats chronically intoxicated by ethanol — animalView study →}.

Gap: Mixed animal data in which picamilon is frequently the weaker comparator; no human neuroprotection outcome evidence at all.

A 1989 study reported that picamilon 10 mg/kg/day accelerated radial-maze learning in rats and improved short-term memory acquisition, whereas piracetam 200 mg/kg/day did not ^{15Reference 15Voznesenskiĭ et al. · 1989Comparative study of picamilone and piracetam on learning in a radial maze — animalView study →}. Related rat work links picamilon to partial normalization of GABA-A receptor complexes and behaviour after hypokinesia-induced anxiety and depression ^{17Reference 17Author(s) · 2006AnimalEffect of hypokinesia on depression and central GABA-A receptor complexes in rat brain — animalView study →}.

Gap: A single positive rodent paradigm; no placebo-controlled human cognition trial in healthy or replete adults.

The consumer “calm” positioning traces to a 1986 rat study in which nicotinoyl-GABA showed anxiolytic activity that — like several other agents tested — was not mediated by benzodiazepine receptors ^{16Reference 16Author(s) · 1986AnimalRole of benzodiazepine receptors in the anxiolytic effect of compounds in rats — animalView study →}. The pharmacokinetic premise is real: the conjugate crosses the blood–brain barrier roughly 10× better than GABA ^{19Reference 19Rozanov et al. · 1993Metabolism and catabolism to CO₂ of [¹⁴C]GABA conjugates with nicotinate, pyridoxal phosphate and biotin — animalView study →}. But no controlled human anxiety trial was located in this review.

Gap: One rodent study, an unclear mechanism, and no human data — and the 2023 finding that intact picamilon does not bind GABA receptors ^{2Reference 2Santillo et al. · 2023In vitroPicamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets — in vitroView study →} weakens the simplest “it’s a GABA drug” explanation for any calming effect. The marketed “anti-anxiety nootropic” use is largely inferential.